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ABSTRACT
Introduction: Chronic heart failure is a cardiovascular disorder with high prevalence and incidence
worldwide. The course of heart failure is characterized by periods of stability and instability.
Decompensation of heart failure is associated with frequent and prolonged hospitalizations and it
worsens the prognosis for the disease and increases cardiovascular mortality among affected patients. It
is therefore important to monitor these patients carefully to reveal changes in their condition. Remote
monitoring has been designed to facilitate an early detection of adverse events and to minimize regular
follow-up visits for heart failure patients. Several new devices have been developed and introduced to
the daily practice of cardiology departments worldwide.
Areas covered: Currently, special tools and techniques are available to perform remote monitoring.
Concurrently there are a number of modern cardiac implantable electronic devices that incorporate a
remote monitoring function. All the techniques that have a remote monitoring function are discussed in
this paper in detail. All the major studies on this subject have been selected for review of the recent
data on remote monitoring of HF patients and demonstrate the role of remote monitoring in the
therapeutic decision making for heart failure patients.
Expert commentary: Remote monitoring represents a novel intensified follow-up strategy of heart
failure management. Overall, theoretically, remote monitoring may play a crucial role in the early
detection of heart failure progression and may improve the outcome of patients.
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1. Introduction
Chronic heart failure (HF) is a cardiovascular disorder with high
prevalence and incidence worldwide. The course of HF is
characterized by periods of stability and instability.
Deterioration of HF is associated with frequent and prolonged
hospitalizations and it worsens the prognosis for the disease
and increases cardiovascular mortality among affected
patients. Globally deaths from cardiovascular disease have
increased by 41% in the period from 1990 to 2013, while
age-specific death rates decreased by 39% [1]. The age-stan-
dardized death rate per 100,000 for heart disease decreased
from 520.4 to 169.1 (67.5% reduction; 95% CI, 67.4–67.6%)
between 1969 and 2013 in the United States [2]. HF affects
approximately 1–2% of the adult population worldwide [3–7].
The incidence of HF remains stable worldwide while the pre-
valence has increased over the recent decades [8,9]. Despite
the current approach to the early diagnosis and treatment HF
mortality remains high, especially in the developing countries
[10–12]. Another important aspect is a high rate of HF-related
admissions and readmissions and subsequent financial expen-
ditures [13–19]. The high rate of readmission among HF
patients associated with decompensation of the disease is
due to a poor adherence to medical therapy, volume overload,
natural course of disease, etc. The management of HF patients
undergoing standard care includes scheduled office visits,
scheduled follow-ups and readmissions due to decompensa-
tion. Intensive follow-up by means of remote monitoring is
currently presented by structured telephone support, teleme-
dicine, remote monitoring with implanted therapeutic and
monitoring-only devices. Remote monitoring systems prevent
potential unfavorable cardiovascular events among HF
patients.
The aim of this article is to review the recent data on
remote monitoring of HF patients and present the role of
remote monitoring in the therapeutic decision-making for HF
patients.
2. Heart failure and device therapy
The European Society of Cardiology (ESC) guidelines defines
HF as a ‘a clinical syndrome characterized by typical symptoms
(e.g. breathlessness, ankle swelling and fatigue) that may be
accompanied by signs (e.g. elevated jugular venous pressure,
pulmonary crackles and peripheral edema) caused by a struc-
tural and/or functional cardiac abnormality, resulting in a
reduced cardiac output and/or elevated intracardiac pressures
at rest or during stress’ [3]. High prevalence, poor quality of
life, high risk of disability, poor prognosis, high rate of hospi-
talizations and readmissions and high level of associated
financial cost make HF a significant public health problem [20].
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In the Framingham study, the incidence of HF was reported
between 1.4 and 2.3 per 1000/year among persons aged 29 to
79 years [21]. The prevalence of HF highly depends on the
applied definition and screening methods. According to the
recent ESC guidelines for the diagnosis and treatment of acute
and chronic HF it’s classified into HF with preserved (HFpEF),
mid-range (HFmrEF) and reduced ejection fraction (HFrEF) [3].
The prevalence of HF among the adult population of developed
countries is approximately 1–2% and ≥10% among people
>70 years old [4–7]. Meantime, the prevalence of unrecognized
HF is high among >65 years old population [22]. It has been
demonstrated in Olmsted County that the age- and sex-adjusted
incidence of HF decreased from 315.8 per 100,000 in 2000 to
219.3 per 100,000 in 2010 (37.5% rate reduction) [23].
Despite the current approach to the early diagnosis and
treatment of HF (i.e. optimal medical therapy (OMT), device
therapy), the prognosis of HF remains poor, though, the inci-
dence and mortality of HF have decreased in western, devel-
oped countries. A 40% reduction of the age-standardized
death rates due to HF has been demonstrated by Laribi et al.
in seven European countries (Germany, Greece, England and
Wales, Spain, France, Finland, and Sweden) in the period from
1987 to 2008 [24]. Between 2000 and 2009, the US age-stan-
dardized death rate from HF has decreased by 13.5% [25].
Despite the demonstrated decline the risk of sudden car-
diac death (SCD) is still high among HF patients, which is
mostly associated with a pump failure and malignant ventri-
cular tachyarrhythmias [10]. Poor outcome of HF patients was
demonstrated in the CONSENSUS (Cooperative North
Scandinavian Enalapril Survival Study) study in 1987 [11].
Important studies around the millennium, such as the
Framingham Heart Study and ARIC study, have demonstrated
that an estimated survival of HF patients after being diag-
nosed is 50% and 10% at 5 and 10 years [12,26–30]. Severe
left ventricular systolic dysfunction is a SCD risk factor among
HF patients [31]. The median survival was 4.2 years among
outpatients in the Henry Ford Health system [32].
The course of HF runs with periods of a stability and
decompensation. Poor adherence to medical therapy, inade-
quate medical therapy, changes in diet, poor self-care and
inadequate patient support, as well as the natural course of
the disease are the main factors responsible for decompensa-
tion of HF. Factors, such a volume overload and persistent
high filling pressures usually accelerate the natural course of
disease [33]. Decompensation of HF often requires an intensi-
fication of treatment, readmission and prolonged in hospital
treatment. HF is still the leading cause of hospitalization
among adults >65 years of age in the USA [15]. HF is respon-
sible for more than 1 million hospitalizations per year in the
USA, which accounts for approximately $17 billion of expen-
diture [34]. Approximately 70% of HF related costs are due to
hospitalization [35]. Hence, HF is considered as a significant
socioeconomic problem, partly due to a substantial direct and
indirect related cost (i.e. $30, and $33 billion respectively in
2006 and 2007 in the USA) [13,14]. The readmission rate
among HF patients remains high and it is the highest within
the first 6 months after an admission due to HF [16–18],
approximately 24% of discharged patients is readmitted
within 30 days due to HF decompensation [19].
3. Remote monitoring in heart failure: rationale
HF decompensation worsens the prognosis for the disease
and increases cardiovascular mortality among affected
patients. Besides, readmissions are associated with substantial
financial cost. Hence, efforts should be made to accomplish
the early detection of HF progression and the possible pre-
vention of life-threatening conditions by timely intervention
and appropriate management of the patients’ treatment.
Possible early prediction and prevention of HF decompensa-
tion may play a crucial role in improving the overall survival
rate among HF patients, a reduction of readmission rates and
substantial saving on costs associated with inhospital treat-
ment, costly interventions and lead to an improvement of
quality of care [36].
Recent guidelines recommend a multidisciplinary care
approach to the management of HF patients [3,37]. The multi-
disciplinary HF care approach includes a standard care (i.e. in-
person follow-up visits) and alternative approaches, most of
which have been presented recently (i.e. regularly scheduled
structured telephone contact between patient and health care
specialist (i.e. trained nurse practitioner, physician), electronic
transfer of physiological data using remote access technology
via external, wearable, or implantable electronic devices [38].
These alternative approaches may potentially provide remote
disease management by continuous or frequent assessment of
some HF related physiological parameters. It may decrease the
number of office visits and increase the efficiency of treatment
through early detection and timely management of worsen-
ing HF.
The number of HF patients with implanted cardiac implan-
table electronic devices (CIEDs) has increased dramatically in
recent decades [20,39]. A substantial number of modern CIEDs
incorporate remote monitoring capability, which allows spe-
cialists to follow patients and access valuable cardiac data and
alert messages from the device while the patient is at home.
Simultaneously, the number of lead-related complications (i.e.
lead failure) has increased because of the growing number of
implantations, greater use of CIEDs in young patients, patients
with more comorbidities, and an increase in device and pro-
cedure complexity [40]. Remote monitoring systems incorpo-
rated in CIEDs may have a potential positive role in the early
diagnosis of lead-related complications before the scheduled
office visit or scheduled device follow-up [41]. Another poten-
tial advantage of remote monitoring systems is an early detec-
tion of silent episodes of atrial fibrillation (AF), because of the
strong association between AF and the risk of developing HF,
increased mortality risk, and increased risk of thromboembolic
(TE) events. The potential harmful effects of unrecognized AF
in patients receiving cardiac resynchronization therapy (CRT),
such as inappropriate shocks and impairment of CRT therapy,
have also been demonstrated [42–48].
In summary, notwithstanding the current approach to the
treatment of HF the rate of decompensation and subsequent
readmission remains high. Meantime, despite a substantial
improvement over time, survival after the diagnosis of HF
remains poor. Remote monitoring which is currently available
in the most of developed and developing countries may play
an important role in prevention of HF decompensation.
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Currently, remote monitoring of HF encompasses struc-
tured trans-telephonic support, telemonitoring, electronic
transfer of physiological data from implanted therapeutic
devices and implanted monitoring-only devices.
4. Remote monitoring of heart failure: tools and
results
4.1. Structured trans-telephonic support and
telemonitoring of HF patients
Structured telephone support and telemonitoring may
become an alternative to the frequent office visits.
Structured telephone support is a telephone consultation
between the patient and physician or a trained nurse. The
patient’s symptoms and body weight play an important role
in the decision-making based on the structured telephone
support. In the systematic review of Inglis et al. 41 rando-
mized clinical trials comparing structured telephone support
(25 studies, 9332 patients) and telemonitoring (18 studies,
3860 patients) with standard care for HF were studied [49].
Telemonitoring was associated with a significant reduction in
all-cause mortality (RR 0.80, 95% CI 0.68–0.94; partici-
pants = 3740; studies = 17; I2 = 24%, GRADE: moderate-
quality evidence) and HF-related hospitalizations (RR 0.71,
95% CI 0.60–0.83; participants = 2148; studies = 8; I2 = 20%,
GRADE: moderate-quality evidence). Structured telephone
support showed decreased all-cause mortality (RR 0.87, 95%
CI 0.77–0.98; participants = 9222; studies = 22; I2 = 0%,
GRADE: moderate-quality evidence) and HF-related hospitali-
zations (RR 0.85, 95% CI 0.77–0.93; participants = 7030; stu-
dies = 16; I2 = 27%, GRADE: moderate-quality evidence)
(Table 1). Neither structured telephone support nor telemo-
nitoring demonstrated effectiveness in reducing the risk of
all-cause hospitalizations (structured telephone support: RR
0.95, 95% CI 0.90–1.00; participants = 7216; studies = 16;
I2 = 47%, GRADE: very low-quality evidence; noninvasive
telemonitoring: RR 0.95, 95% CI 0.89–1.01; participants = 3332;
studies = 13; I2 = 71%, GRADE: very low-quality evidence). In
the Tele-HF study (Telemonitoring to Improve Heart Failure
Outcomes) 1653 patients were included and randomized to
telemonitoring care (826 patients) or standard care (827
patients) groups [50]. Readmission rates and deaths did not
significantly differ between these two groups. Telemonitoring
involved an interactive voice-response system that trans-
mitted daily information about symptoms and weight to the
clinicians. Only 55% of patients included in the telemonitor-
ing group used the system at least three times per week by
the end of the study, and 14% of patients never used the
system. A total of 710 patients with stable HF were included
and randomized to telemedical care (354 patients) or stan-
dard care (356 patients) groups in the TIM-HF study
(Telemedical Interventional Monitoring in Heart Failure) [51].
Portable devices transferred encrypted data including electro-
cardiography, blood pressure and body weight via cell
phones to the specialized telemedical centers. There were
no significant differences in HF hospitalization among these
two groups at a mean of 26 months on follow-up (hazard
ratio (HR), 0.89; 95% CI, 0.67–1.19; P = .44).
Controversial results of clinical trials have been published
regarding the remote management (i.e. telemedicine) in HF
patients. Some other meta-analyses suggest clinical benefit,
but several prospective clinical trials, such as Tele-HF, TIM-HF,
INH, WISH and TEHAF have not confirmed it [50–54]. Hence,
different telemedicine approaches have to be assessed on
their individual merit.
4.2. Remote monitoring with implanted therapeutic
devices
The number of HF patients with CIEDs has increased in recent
decades [39]. A substantial number of modern CIEDs are
equipped with remote monitoring capabilities. Remote mon-
itoring of implantable cardioverter defibrillators (ICD) and CRT
devices allow wireless download and stored diagnostic infor-
mation from device to an external transmitter and transfer to
the manufacturer’s database. The data can be made available
to the clinician through a specific interface [55]. Many para-
meters can be remotely monitored with potential implications
for the clinicians’ decision-making. These include diagnosis of
disease deterioration and prevention of acute decompensa-
tion. Furthermore, technical features of the devices (antitachy-
cardia pacing, DC shock, ventricular pacing percentage) and
so-called ‘heart failure diagnostic’ parameters, such as thoracic
impedance, heart rate variability, presence of arrhythmias,
patients’ activity level, mean heart rate at rest and exertion,
can also be remotely monitored.
4.3. Detection of heart rhythm disorders
Identification of cardiac rhythm disorders (such as AF, prema-
ture ventricular complexes, etc.) among HF patients is impor-
tant in the patients’ daily management and in the prevention
of potential complications. The prevalence of AF among HF
patients is about 13–27%. Early diagnosis and management of
AF may prevent AF-associated complications and worsening
of the HF course [56–60]. Clinically silent arrhythmias, parti-
cularly silent episodes of AF may be diagnosed and registered
in patients with CIEDs. This is a major advantage to patients
with implanted CIEDs over patients without continuous mon-
itoring. In the ASSERT study 34.7% of the 2580 patients, with-
out a prior history of AF, experienced an episode of newly
detected AF with more than 6 min of duration (during
2.5 years of follow-up) [61]. In 30% of patients included in
the TRENDS trial (1368 patients with no history of AF, no
previous stroke/TIA, no warfarin or antiarrhythmic drug use)
experienced an episode of a newly detected AF (i.e. an epi-
sode of AF lasting more than 5 min on any day of the study)
[62]. Approximately 62% of these patients with newly
detected episodes of AF had a CHADS2 score of more than
1. The association between device detected AF and the risk of
stroke has also been demonstrated (Table 1). In the ancillary
MOST trial episodes of AF with more than 5 min of duration
have clinical significance [63]. Data analysis from the EVEREST
and HomeCARE studies (560 patients) has shown that patients
with newly detected AF and those with a prior history of AF
had more chance of experiencing thromboembolic events
than those without newly detected AF episodes [64].
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Considering the aforementioned data, the patient manage-
ment can be changed in response to the detection of an
asymptomatic episode of AF. This is of particular importance
given the fact that in the light of the recent data, the routine
oral anticoagulation use in chronic HF patient has been
dropped [3]. Possible delay (i.e. infrequent office visits) may
be associated with an increased risk of thromboembolic (TE)
complications. The latter can be prevented by remote mon-
itoring with implanted CIEDs. In 20% of 166 included patients
(single-center study; 73% pacemakers; 27% ICDs; 16 months
of follow-up) had alerts triggered by AF [65]. In 88% of these
patients clinical intervention (i.e. drug therapy modification,
device reprogramming, electrical cardioversion) was required.
More than 3 million transmissions were sent by 11,624
patients with implanted ICDs and CRTDs included in the
worldwide Home Monitoring database [66]. Around 60% of
these alerts were due to AF episodes. The TRUST trial included
1339 patients with ICDs [67]. AF detection occurred at
5.5 days in the remote monitoring group compared with
40 days in the standard follow-up group. A total of 1997
patients with implanted ICDs were followed for 15 months
in the CONNECT trial [68]. The interval between AF episode
detection and clinical response was eight times shorter in the
remote monitoring group compared with the standard follow-
up group (3 vs. 24 days). Despite the presented data, cur-
rently, there is limited evidence suggesting that remote mon-
itoring is associated with reduced risk of AF-related
complications. Results from the Monte Carlo simulations sug-
gested that daily monitoring could reduce the 2-year stroke
risk from 18% to 9% for an absolute reduction from 0.6% to
0.2% per every 2 years, compared to conventional follow-up
at intervals of 6–12 months [69]. The COMPAS randomized,
multicenter, non-inferiority trial (538 patients randomized to
remote monitoring follow-up vs. standard care) examined the
safety of long-term remote monitoring of pacemakers [70].
During an 18.3 months follow-up there were 17.3% vs. 19.1%
(P < .01 for non-inferiority) patients who experienced at least
one major adverse event (all-cause death, hospitalizations for
device-related or cardiovascular events) in the remote mon-
itoring group and standard care group, respectively.
Hospitalizations for atrial arrhythmias (6 vs. 18) and strokes
(2 vs. 8) were fewer (P < .05), and the number of interim
ambulatory visits was 56% lower (P < .001) in the remote
monitoring than the standard care group. However, no
improvement in the outcome of stroke or all-cause mortality
was demonstrated in the IMPACT study [71].
Overall, around one-third of patients with implanted CIEDs
experienced asymptomatic episodes of AF. Patients from this
cohort have an increased risk of TE complications. Remote
monitoring is a unique technique for the early detection of
asymptomatic episodes of AF and early management. The
potential benefits have to be proven by the further studies.
Heart rate variability (HRV) as a measure of an autonomic
function has been of interest. Aronsov et al. have demon-
strated that a decrease in HRV is associated with a worsening
of HF and an increased risk of death [72]. Meanwhile,
Adamson et al. have demonstrated in 288 patients with
NYHA class III to IV that an automated algorithm to detect
decreases in heart rate variability had 70% sensitivity for
predicting detecting hospitalization but was associated with
a high false-positive rate [73].
4.4. Detection and management of system-related
complications in patients with implanted CIEDs
As mentioned above, remote monitoring may play an impor-
tant role in the early diagnosis and management of system-
related complications in patients with implanted CIEDs [41].
The number of CIED implantations among HF patients has
increased exponentially. Expert consensus advises in-clinic
checks at 3–6-monthly intervals with increased frequency in
response to product advisories [55]. Unfortunately, patients
with implanted CIEDs experience a significant number of sys-
tem-related complications. The majority of which are lead-
related complications (due to insulation defect or conductor
disruption). The annual failure rate of 10-year-old defibrillation
leads is approximately 20% [74]. A significant number of
observational studies and randomized clinical trials have
demonstrated the beneficial effect of remote monitoring on
outpatient management of ICD patients [75–82]. The TRUST
trial has shown that remote monitoring is safe and allows
earlier detection of events as compared with standard fol-
low-up [83]. Spencker et al. have performed a retrospective
cohort analysis of 54 patients with an ICD lead failure [84]. The
authors have concluded that in 91% of all lead-related ICD
complications, the diagnosis could be established correctly by
an alert from the remote monitoring system. A total of 40
recipients of a high-voltage lead, prone to fracture, were
remotely followed in the ECOST (Effectiveness and Cost of
ICDs Follow-up Schedule with Telecardiology) trial [80]. Over
a mean follow-up of 22 ± 4 months after implantation, the
failure rate was 7.5%. Remote Monitoring allowed the early
and reliable detection of three lead fractures, manifested by
the sensing of noise artifact, abrupt rise in pacing impedance,
or both, without requiring the intervention of patients in the
diagnosis or decision-making process (Table 1).
The results of these studies emphasize the need for con-
tinuous monitoring of implanted defibrillation systems.
Remote monitoring of devices offers the possibility of contin-
uous observation, early detection of lead failures and fast
decision-making.
4.5. Detection of hemodynamic deterioration in heart
failure patients
Many commercially available CIEDs enable the measurement
of intrathoracic impedance that may predict HF decompensa-
tion since the majority of HF patients demonstrate volume
overload in the pulmonary circulation caused by an elevated
left ventricular (LV) filling pressure. Yu et al. have demon-
strated in 33 patients with NYHA class III and IV HF that
intrathoracic impedance is inversely correlated with pulmon-
ary capillary wedge pressure and fluid balance and typically
decreased before patient become symptomatic [85]. Abraham
et al. demonstrated the superiority of intrathoracic impedance
monitoring compared with daily weight monitoring in
patients with mild to moderate chronic systolic HF in patients
with implanted devices (ICD, CRTD) for the first time in 2011
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[86]. A reasonable balance between sensitivity and specificity
of intrathoracic impedance measurement was demonstrated
by Ypenburg et al. in patients with implanted InSync Sentry
CRTDs [87]. In contrast to the results of earlier studies,
Conraads et al. have demonstrated in the SENSE-HF trial (501
patients) that an intracardiac impedance-derived fluid index
had low sensitivity and positive predictive value in the early
period (6 months) after implantation of a device in chronic HF
patients. Meanwhile sensitivity improved within the first
6 months after implantation [88]. Similar results have been
demonstrated by van Veldhuisen et al. in the DOT-HF
(Diagnostic Outcome Trial in Heart Failure) study that included
335 patients with an implanted CIED [89]. Patients were ran-
domized to have information available to physicians and
patients as an audible alert when a preset threshold was
crossed (access arm) or not (control arm). Treatment guided
by routine monitoring of intrathoracic impedance was not
associated with a better outcome but was associated with an
increased likelihood of HF hospitalization. The impedance
monitoring has been scrutinized in the PARTNERS-HF trial
(Program to Access and Review Trending Information and
Evaluate Correlation to Symptoms in Patients with Heart
Failure) [90]. Patients with implanted CRT-Ds (Medtronic
devices equipped with intrathoracic impedance monitoring
called Opti-Vol) were enrolled. It was demonstrated that
reduced impedance (or increased fluid index) was the most
sensitive parameter to predict HF hospitalizations. Cowie et al.
published the study for the development and validation of a
dynamic heart failure score based on the following parameter
monitored by implanted ICDs or CRTs: intrathoracic impe-
dance, heart rate variability, arrhythmia burden and patient
activity [91]. The data set consisted of 921 patients with an
average follow-up duration of 10.6 ± 5.8 months. They demon-
strated that patients with a high-risk score have a 10 times
more chance of hospitalization compared to patients with a
low score. It is not clear whether clinical actions initiated by
the stratified risk will have a positive impact on the course of
HF or not. The IN-TIME prospective, randomized, controlled,
multicenter trial analyzed 664 patients with NYHA class II and
III with implanted ICDs and CRTDs [92]. Patients were rando-
mized to either standard care or to remote monitoring. In the
telemonitoring group, in response to telemonitoring observa-
tions, the investigators initiated a standardized telephone
interview to establish whether the patient’s overall condition
or symptoms had worsened or not, whether there was a
sudden increase in body weight (>2 kg within the preceding
3 days) or if a visit to the family doctor was scheduled. There
were 63 patients (18.9%) with a declining composite clinical
score in the telemonitoring group compared with 90 patients
(27.2%) in the control group (P = .013). Mortality among
patients involved in the telemonitoring group was lower com-
pared to the control group (n = 10 vs. 27). There were no
significant differences in hospitalization between these
groups. Results of the world’s largest remote monitoring
study REM-HF trial (Remote Management of Heart Failure
Using Implantable Electronic Devices) was recently presented
at the ESC Congress 2016 [93]. A total of 1650 HF patients with
implanted CIEDs (ICD, CRTP, CRTD) featuring remote monitor-
ing were enrolled in the study and were randomized to
receive either standard care (824 patients) or remote monitor-
ing (826 patients). The median follow-up was 2.8 years.
Medical treatment and management of patients (possible
medication and lifestyle changes, need for additional clinic
visits, recommendations to visit their general practitioner or
the emergency room) who received a remote monitoring was
based on the data healthcare professionals received on a
weekly basis from the device. Patients in standard care
group received conventional care from the heart failure ser-
vice and remote monitoring of the device (once per
3–6 months). There were no significant differences neither in
the primary end point (death from any cause or unplanned
hospitalization for cardiovascular causes) nor in the secondary
end point (death from any cause, death from cardiovascular
diseases, unplanned hospitalization). Hence, the REM-HF trial
demonstrated that remote monitoring was not associated
with reduced mortality or fewer cardiovascular hospitaliza-
tions compared to standard care (Table 1).
Recently, the MORE-CARE (Monitoring Resynchronization
Devices and Cardiac patients) prospective, multicenter, rando-
mized controlled trial has been published, which evaluates the
clinical efficacy and safety of remote monitoring compared with
standard follow-up strategies in HF patients implanted with
biventricular ICD [94]. A total of 865 patients were included and
randomized into a remote arm (n = 437; remote checks alternat-
ing with in-office follow-ups) and a standard arm (n = 428; in-
office follow-ups). The primary end point of the study was a
composite of death and hospitalization due to cardiovascular
and device-related causes. There were no significant differences
in the primary end point between these two groups. There was a
significant 38% reduction in healthcare resources utilization in
the remote arm (i.e. 2-year rates of cardiovascular hospitaliza-
tions, cardiovascular emergency department admissions, cardio-
vascular in-office follow-ups) as compared with the standard
arm. This is mainly explained by a reduction of in-office visits,
despite a slightly higher rate of unscheduled visits in the remote
arm (IRR: 2.80, 95% CI 2.16–3.63, P < .001).
Hindriks et al. performed a meta-analysis of the TRUST,
ECOST and IN-TIME trials [95]. Pooled data-analysis of 2405
patients, demonstrated that remote monitoring with Biotronik
Home Monitoring was associated with a 38% reduction in all-
cause mortality as compared with conventional office follow-
ups alone after 1 year of follow-up. The combined risk of all-
cause mortality or hospitalization for HF decompensation was
36% lower in the remote monitoring group.
The presented results demonstrated that remote monitoring
with implanted therapeutic devices may play an important role
in an early diagnosis of HF decompensation. Meanwhile, signifi-
cant differences exist between devices from different manufac-
turers (with respect to system technologies and feasibilities, data
acquisition capabilities, process and workflow options), which
can have an impact on their effectiveness to improve outcomes.
4.6. Detection of sleep disorders: the potential
implementation of remote monitoring
Patients with HF often complain of sleep disorders such as
sleep fragmentation or nonrestorative sleep, difficulties in
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initiating sleep, or waking up too early in the morning [96].
Insomnia is more common among HF patients compared to
the general population (33% vs. 10–15%), which can be asso-
ciated with mood disorders and psychological stress [97]. HF
patients can have secondary insomnia due to HF itself or from
the adverse effects of prescribed medication (angiotensin-
receptor blockers, loop diuretics, β-blockers, and statins) [98].
The prevalence of sleep-related breathing disorders is high
among HF patients, which is reported to have an important
added prognostic value in HF [97]. Sleep-disordered breathing
is presented in two major forms: obstructive sleep apnea
(OSA) and central sleep apnea (CSA). OSA results from the
complete collapse of the pharyngeal soft tissues, mainly soft
palate and tongue base, CSA arises from fluctuations in the
central respiratory drive [97]. A mixed sleep apnea is a third
form of sleep-disordered breathing and characterized by an
initial central apnea event followed by an obstructive compo-
nent. Nearly 50% of HF patients have central or obstructive
apneas and hypopneas that decrease the positive effects of
physiological sleep on the cardiovascular system [99,100].
Sleep-disordered breathing is associated with a high sympa-
thetic activation which can negatively affect the prognosis of
HF patients [101–103]. Continuous positive airway pressure
(CPAP) is a treatment modality for patients with OSA. CPAP
therapy in patients with HF and OSA prevents recurrent
hypoxia, reduces nocturnal blood pressure and heart rate,
and increases arterial baroreflex sensitivity [104,105]. CPAP
treatment was associated with a significant increase in a
mean LV ejection fraction (LVEF) and reduction in dyspnea in
the study of Malone et al. published in 1991 [106]. It was the
first study which demonstrated the positive influence of CPAP
therapy in HF patients. Kauta et al. have demonstrated that
CPAP therapy was associated with a reduced hospital read-
mission rate and emergency department visits of HF patients
over a 30-day observation period [107]. Randomized trials
have also demonstrated the association between CPAP ther-
apy and LVEF improvement, reductions in blood pressure,
heart rate and sympathetic nerve activity [108,109]. A meta-
analysis of 10 randomized clinical trials performed by Sun et al.
has demonstrated that CPAP therapy may significantly
improve LVEF in HF patients [110]. However, there are no
randomized controlled trials demonstrating the effect of
CPAP therapy on mortality among HF patients with OSA. In
addition, the scientific statement on sleep apnea and cardio-
vascular disease from the AHA/ACC Foundation considers
CPAP treatment in patients with HF as being investigational
because this treatment option is not supported by rando-
mized trial data [111].
CIEDs with incorporated Sleep Apnea Monitoring (SAM)
system have been recently developed. SAM has been
designed to detect, count and report breathing disorders dur-
ing the night. A total of 40 patients with indications for pace-
maker implantation were involved in the DREAM European
study [112]. Sleep apnea diagnosis was confirmed by poly-
somnography as a gold standard diagnostic technique and
compared with the respiratory disturbances index evaluated
by the SAM algorithm complied from the device during the
same diagnosis night (Table 1). The study has demonstrated
that an advanced algorithm could be used to identify sleep
apnea in patients with pacemakers outside the clinic or at
home.
The results of these studies emphasize the need for the
further research in the sphere of CPAP therapy in HF patients
with OSA. CIEDs with incorporated sleep apnea detection
facilities and remote monitoring may play a crucial role in
the early detection of OSA in HF patients and improvement
of hemodynamics with CPAP therapy. Whether the latter will
improve the survival among HF patients has to be clarified by
randomized trials.
4.7. Remote monitoring with implanted monitoring-only
devices
Implanted monitoring-only devices are hemodynamic moni-
tors measuring intracardiac or intravascular pressures. These
monitors presented by right ventricular, pulmonary artery and
left atrial pressure monitors. The basic pathophysiology of HF
(i.e. cardiac filling pressures determine the clinical symptoms
and course of HF) lies behind the idea of using such monitors
in clinical practice [113].
Medtronic Inc has developed the Chronicle, implantable
hemodynamic monitor, which is a long-term implanted device
consisting of a subcutaneously implanted generator and a
unipolar transvenous pacemaker lead, carrying a pressure
sensor, positioned in the RV outflow tract that records RVSP,
RVDP and estimation of PAP. A total of 274 patients with
NYHA class III-IV HF on optimal medical therapy were included
in the COMPASS-HF (Chronicle Offers Management to Patients
with Advanced Signs and Symptoms of Heart Failure) prospec-
tive, multicenter, randomized, single-blinded, parallel-con-
trolled trial and randomized into the Chronicle device group
(n = 134) and standard group (n = 140) [114]. Primary end
points of the study were freedom from system-related com-
plications, freedom from pressure sensor failure and reduction
in the rate of HF-related hospitalizations or emergency visits
(Table 1). The complication-free rate was 91.5% at 6-month of
follow-up. A statistically nonsignificant reduction in HF admis-
sions or urgent follow-up visits by 21% (P = .33) in the
Chronicle group has been demonstrated. A retrospective ana-
lysis has shown a statistically significant 36% reduction in
relative risk of the time to first hospitalization in the
Chronicle group. A new trial, REDUCEhf was designed to enroll
850 patients (then increased to 1300) with an indication for
ICD (NYHA class II-III, impaired LV ejection fraction) therapy, to
test whether use of RV pressure-guided patient management
would reduce HF-related adverse events or not [115]. The trial
was prematurely terminated due to technical complications
after the enrolment of 400 patients. No benefit from hemody-
namic monitoring was been demonstrated.
St Jude Medical (acquired by Abbott) has developed a
catheter-delivered pressure sensor (15-mm long, 3-mm wide)
that is permanently implanted in the pulmonary artery via
right heart catheterization, called Cardio-MEMS. The device
consists of a wireless 3D coil and a pressure-sensitive capacitor
covered with silicone. A total of 550 patients with NYHA class
II HF were included in the CHAMPION (CardioMEMS Heart
Sensor Allows Monitoring of Pressure to Improve Outcomes
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in NYHA Class II Heart Failure Patients) prospective, multicen-
ter, single-blind clinical trial and randomized either to the
CardioMEMS (n = 270 patients) or standard monitoring
(n = 280 patients) groups [116]. The study has demonstrated
a statistically significant reduction in HF hospitalization
(regardless of LV ejection fraction) by 28% and 37% in the
CardioMEMS group over a 6- and 15-month follow-up, respec-
tively. Rates of non-HF-related hospitalizations were similar in
both groups. Patients included in the CardioMEMS group had
a significant reduction in the mean pulmonary artery pressure
and better quality of life during the 6-month follow-up based
on the Minnesota Living with Heart Failure Questionnaire.
St Jude Medical (acquired by Abbott) has also developed a
HeartPOD device to directly measure LA pressure, core tempera-
ture and intracardiac electrograms, by a sensor lead placed
intra-atrially through a transseptal puncture, which is then
linked to a sub-pectoral antenna. A total of 40 patients with
NYHA class III-IV HF were included in the HOMEOSTASIS
(Hemodynamically Guided Home Self-Therapy in Severe Heart
Failure Patients) prospective, observational, first-in-human
study. The follow-up period was divided into three parts: the
first 3 months (patients and clinicians were blinded to LA pres-
sure readings), the second 3 months was a titration period
(therapy adjustment to find an optimal LA pressure), and stabi-
lity period (therapy adjustment to maintain an optimal LA pres-
sure) [117]. The total follow-up period of the study was
25 months. Patients included in the HeartPOD group had statis-
tically significant improved control of LA pressure, improvement
in NYHA class, enhanced neurohormonal antagonist dosing and
a 59% reduction of clinical events in the titration and stability
periods as compared with the observation period.
Overall, theoretically, implantable hemodynamic monitor-
ing devices may play an important role in the early detection
of HF decompensation. However, there is no clear evidence in
regard to the sensitivity of such devices in the early detection
of HF decompensation. The latter has to be demonstrated in
large randomized trials.
5. Expert commentary
Clinical management to prevent acute decompensation and/
or readmission in ambulatory HF patients remains challen-
ging. Overall, chronic HF is the ‘oncological’ cardiac disease
with grave prognosis, unless appropriate optimal medical
and device based therapies are instituted. Once the
unstable, decompensation periods begin, the progression
of HF is usually irreversible. Consequently, efforts should
be made to decrease HF incidence and prevalence and
improve survival among HF patients by the early detection
of disease deterioration and timely changes in the treatment
of affected patients. A number of new techniques for the
diagnosis and treatment of HF have been developed and
introduced into clinical practice. Remote monitoring is a
spectacular tool in the arsenal of cardiologists that has
been designed to facilitate an early detection of adverse
events and to minimize regular follow-up visits of HF
patients. Nowadays, several possible tools are available for
the remote monitoring of HF. Structured trans-telephonic
support and telemedicine has shown variable clinical results
in prevention of the deterioration of HF. The data on remote
monitoring of HF patients with CIEDs are still controversial,
due to the presence of significant differences in different
manufacturers’ devices (system technologies and feasibil-
ities, data acquisition capabilities, process and workflow
options). Meanwhile, remote monitoring is feasible and
may facilitate early detection of system-related complica-
tions. However, as with every new technology, there are
areas of uncertainty. Because there is not one universal
approach, each device needs to be assessed on its individual
merit in individual patients. The biggest challenge is to
provide a platform which will allow the rapid and simple
interpretation of the remote monitoring data that produces
a targeted and effective response. The diagnostic, therapeu-
tic and preventive potential of remote monitoring remains
undefined in terms of cost/risk/benefit ratio. This is currently
one of the limitations of such devices.
Overall, early intervention in response to remote moni-
toring registration may help to prevent the decompensation
of HF. Meantime, remote monitoring provides a large
amount of information. Further research by way of rando-
mized clinical trials has to identify the parameters which
play the most important role in the management of HF
patients.
6. Five-year view
Recently published trials on remote monitoring call to
develop the next generation of tools with better algorithms
to help triage alerts and simplify interpretation of data,
directed to impact clinical outcomes. The next generation
of remote monitoring technology would be developed to
identify what is important in all the data streams and also
enable nurses, technologists and physicians to know what
action to take at the right time. The whole system of remote
monitoring can be more visionary and, which is very impor-
tant, more user friendly (e.g. simple and understandable
programming of devices and recorded information retrieval).
Further improvement in the technical aspects will allow the
reduction in the rate of false alarms. Wireless charging of
implanted CIEDs may become an alternative to frequent
device changes. Most probably the future generation of
CIEDs will incorporate pressure sensors which will allow a
continuous monitoring of intracardiac and intravascular
pressures. Continuous blood pressure monitoring and better
LV lead performance, direct coupling to medication change,
self-assessment based medication changes, possible involve-
ment of mobile devices with specifically developed applica-
tions and artificial intelligence will improve management
and outcome of HF patients.
Key issues
● Chronic HF is a cardiovascular disorder that affected
approximately 1–2% of adult population worldwide.
● Incidence and mortality of HF are decreasing in developed
countries.
● The course of HF is characterized by periods of stability and
instability. Deterioration of HF is associated with frequent
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and prolonged hospitalizations and it worsens the prog-
nosis for the disease and increases cardiovascular mortality
among affected patients.
● Remote monitoring has been designed to facilitate an early
detection of adverse events and to minimize regular follow-
up visits for heart failure patients.
● The data on remote monitoring of HF patients with CIEDs
are still controversial, due to the presence of significant
differences in different manufacturers devices (system tech-
nologies and feasibilities, data acquisition capabilities, pro-
cess and workflow options).
● As with every new technology, there are areas of uncer-
tainty. The diagnostic, therapeutic and preventive potential
of remote monitoring is still undefined in terms of cost/risk/
benefit ration.
● A special platform has to be invented to make daily use of
all the recorded information fast and easy.
● The whole system of remote monitoring can be more
visionary and, which is very important, more user friendly.
Further improvement in the technical aspects will allow the
reduction in the rate of false alarms.
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